Citius Pharmaceuticals Inc.

Executive Summary

Citius Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing innovative treatments for cancer and infectious diseases. In April 2026, the company closed a registered direct offering of $5 million at market pricing under Nasdaq rules, bolstering its working capital to advance its pipeline. The company's lead candidates include a novel immunotherapy for hematologic malignancies and an anti-infective agent for resistant pathogens, both targeting high unmet medical needs. With a lean operational model and a focus on late-stage clinical assets, Citius aims to deliver first-in-class therapies to patients. The recent capital raise is expected to fund key milestones such as clinical trial initiations and potential regulatory filings. However, the company's near-term financial position remains limited, and execution risks are present as it navigates competitive landscapes and regulatory pathways. Overall, Citius presents a speculative opportunity contingent on successful development and commercialization of its pipeline, with the recent financing providing a modest runway to reach pivotal data readouts.

Upcoming Catalysts (preview)

• Q4 2026Enrollment completion for phase 2 immuno-oncology trial70% success
• Q2 2027Top-line data from phase 2 anti-infective trial55% success
• Q3 2026Pre-IND meeting with FDA for new oncology candidate80% success